Welcome to MyCLL
This website is intended only for UK patients who have been prescribed Calquence▼ (acalabrutinib). This website has been produced and funded by AstraZeneca.
Please select the relevant option:
What are you looking for today?
GB-69340 | August 2025
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information, and you can help by reporting any side effects you may get. See below for more information.
Reporting side effects
If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in the Patient Information Leaflet. You can also report side effects directly via the Yellow Card Scheme, website: http://yellowcard.mhra.gov.uk/. By reporting side effects you can help provide more information on the safety of medicines.
Side effects can also be reported to AstraZeneca in the following ways:
This website is only intended for UK patients who have been prescribed Calquence (Acalabrutinib). It does not replace the Patient Information Leaflet, which can be found in the carton containing your medicine and should be read alongside this information. If you have any questions about your treatment, talk to your healthcare team or refer to the Patient Information Leaflet.
All patient images are for illustrative purposes only.
